Boehringer's Empagliflozin Heads To Advisory Cmte. With Questions On Treatment Effect

 
• By Michael Cipriano
  
Diabetes
A US FDA advisory committee will assess Boehringer Ingelheim's empagliflozin for a type 1 diabetes indication.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers